Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30236599 | 0.90 | TSHR (1.00) | AKR1B1TSHRTDP1 | |
| SCHEMBL17605022 | 0.90 | TSHR (1.00) | AKR1B1TSHRTDP1 | |
| SCHEMBL17606122 | 0.90 | TSHR (1.00) | AKR1B1TSHRTDP1 | |
| SCHEMBL10599632 | 0.90 | TSHR (1.00) | AKR1B1TSHRTDP1 | |
| SCHEMBL11154103 | 0.84 | AKR1B1 (0.73) | AKR1B1TSHRTDP1CASP6 | |
| SCHEMBL11379499 | 0.84 | AKR1B1 (0.73) | AKR1B1TSHRTDP1CASP6 | |
| SCHEMBL11341929 | 0.80 | AKR1B1 (0.67) | AKR1B1TSHRTDP1 | |
| SCHEMBL11348571 | 0.80 | AKR1B1 (0.67) | AKR1B1TSHRTDP1 | |
| SCHEMBL448629 | 0.80 | AKR1B1 (0.67) | AKR1B1TSHRTDP1 | |
| SCHEMBL11344787 | 0.80 | AKR1B1 (0.67) | AKR1B1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-7439383-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| EP-0115133-B1 | SPIRO-3-HETERO-AZOLONES FOR TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4556670-A | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0115133-A1 | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0028485-B1 | SPIRO-IMIDAZOLONES FOR ALLEVIATING DIABETES-ASSOCIATED CONDITIONS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1983-08-24 | — | — | EP | disclosed |
| US-4283409-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1981-08-11 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | AKR1B1 84/4885TSHR 396/4885TDP1 1693/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | AKR1B1 567/4885TSHR 647/4885TDP1 2690/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | AKR1B1 69/4885TSHR 504/4885TDP1 1667/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | AKR1B1 84/4885TSHR 396/4885TDP1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.